Aktiesnakken — Juni 2013
-
så har de virkeligt skåret til. i gamle dage havde de mange forskellige.
-
mornings
-
Selskaberne har siden 2012 foretaget in-vitro og in-vivo studier for at undersøge forskellige "warhead" og "linker"-kombinationer med HuMax-TAC, og de har nu et produkt klar til præklinisk udvikling forud for en IND-ansøgning. Produktet vil blive udviklet til en række cancerindikationer.
-
Sådan Genmab
-
ADC var lige hvad vi manglede
-
Nu bliver sukker glad
han har længe skreget på mere ADC samarbejde -
ja eller Solsen det er kun indtil IND det er uden omk.
-
derefter kan de beholde 25% uden omk. eller få 50% og deltage i omk.
-
We have an increasingly optimistic view of Daratumumab, which is
currently being developed against multiple myeloma, which we believe will
have peak sales of DKK 17.6bn -
Jeg skal nørde noget Zealand senere idag. De kommer med data fra en helt ny præklinisk kandidat!
-
At the congress, Zealand will present preclinical data on ZP-GA-1, its own proprietary liquid glucagon analogue, which show the potential use for this compound in the treatment and/or prevention of severe hypoglycemia.
“A novel glucagon analogue, ZP-GA-1, displays increased chemical and physical stability in liquid formulation” – Poster
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind